par Esteban, Emilio;Villanueva, Noemi;Muñiz, Isabel;Fernández, Yolanda;Fra, Joaquin;Luque, Maria;Jiménez, Paula;Llorente, Beatriz;Capelan, Marta ;Vieitez, José M;Estrada, Enrique;Buesa, José M;Jiménez-Lacave, Angel
Référence Investigational new drugs, 26, 1, page (67-74)
Publication Publié, 2008-02
Référence Investigational new drugs, 26, 1, page (67-74)
Publication Publié, 2008-02
Article révisé par les pairs
Résumé : | Studies with the gemcitabine/vinorelbine (GV) or the gemcitabine/docetaxel (GD) combinations have shown similar efficacy and less toxicity compared to platinum-based chemotherapies, in patients with advanced non-small-cell lung cancer (NSCLC). The present trial was designed to test the efficacy and safety of both, GV and GD, combinations. Chemotherapy-naïve patients (n=39) |